ACTL6A and cancer: A recent analysis of TCGA data from cBioPortal found that BRD9 was amplified in bladder cancer, lung squamous cell carcinoma, lung adenocarcinoma, esophageal carcinoma, and ovarian cancer, with several of these cancer types also displaying BAF53a amplification [128] (see Fig. 3).